Curocell, Inc.

As of June 30, 2026, Curocell, Inc. carries a market capitalization of 471.99B, placing it among publicly traded companies globally. Its enterprise value stands at 449.95B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Curocell, Inc. has 15.18M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Curocell, Inc. maintains a current ratio of 1.82, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 83.22, indicating elevated leverage, while an interest coverage ratio of -5.35 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Curocell, Inc. posted a negative return on equity (ROE) of -106.47, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -39.18, reflecting losses generated across the asset base.

Over the twelve months ended June 30, 2026, Curocell, Inc. recorded 1.19M in income tax expense. The company reported a pretax loss of -54.08B and -54.08B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Curocell, Inc.'s stock has declined approximately 40.26% over the past 52 weeks. The 50-day moving average sits at 23,658.00, while the 200-day moving average is 37,887.50.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -29.08B, while operating income came in at -35.44B.

As of June 30, 2026, Curocell, Inc. holds 82.70B in cash and equivalents against 60.35B in total debt, resulting in a net debt position of 41.52B. Total book value stands at 72.22B, with working capital of 40.46B providing operational flexibility.

Curocell, Inc. produced -30.00B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.74B in capital expenditures, free cash flow totaled -31.75B - equivalent to -2,165.48 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -6.96: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -18.23, meaning Curocell, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.